公开(公告)号：WO2012103684A1

公开(公告)日：2012-08-09

申请号：PCT/CN2011/070875

申请日：2011-02-01

Applicant: TIANJIN XIJI BIOTECHNOLOGY CO., LTD. ,  RAO, Pingfan ,  LIU, Shutao

Inventor： RAO, Pingfan ,  LIU, Shutao

IPC: A61K38/44 ,  A61P31/18

CPC classification number: A61K38/446 ,  A61K9/0031 ,  A61K9/006 ,  A61K31/506 ,  A61K31/536 ,  A61K31/7072 ,  A61K38/08 ,  A61K38/45 ,  A61K45/06 ,  A61K47/67 ,  B82Y5/00 ,  C07K7/06 ,  C07K14/4711 ,  C07K2319/03 ,  C07K2319/036 ,  C12N9/0089 ,  C12N9/1088 ,  C12Y115/01001 ,  C12Y205/01018

Abstract: The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretro viral agents for treating patients with AIDS or HTV infection.

Abstract translation: 本发明公开了使用包含超氧化物歧化酶和转运肽的融合蛋白的药物组合物和方法。 本发明还公开了使用融合蛋白与其他抗病毒药物组合治疗AIDS或HTV感染患者的药物组合物和方法。

公开(公告)号：WO2011026898A3

公开(公告)日：2011-11-10

申请号：PCT/EP2010062871

申请日：2010-09-02

Applicant: UNIV BANGOR ,  GWENIN CHRISTOPHER ,  KALAJI MAHER ,  ROBERTS VANESSA

Inventor： GWENIN CHRISTOPHER ,  KALAJI MAHER ,  ROBERTS VANESSA

IPC: A61K47/48 ,  A61P35/00

CPC classification number: A61K47/48361 ,  A61K47/67 ,  A61K47/6923 ,  B82Y5/00

Abstract: The present invention discloses a drug activator carrier comprising: a) particles having a metallic or metallic oxide core prepared from a paramagnetic material, said metallic core being coated with a coating material selected from polymer, metal or metal oxide; b) a biological material, having reductase activity, bound onto the metal coating the particles of step a), and wherein said biological material is capable of activating non-toxic pro-drugs into active and toxic drugs suitable for treating a disease; said drug activator carrier allowing targeted delivery of the toxic drug.

Abstract translation: 本发明公开了一种药物活化剂载体，其包含：a）具有由顺磁性材料制备的金属或金属氧化物核的颗粒，所述金属核用选自聚合物，金属或金属氧化物的涂覆材料涂覆; b）具有还原酶活性的生物材料结合到涂覆步骤a）的颗粒的金属上，并且其中所述生物材料能够将无毒的前药活化成适用于治疗疾病的活性和毒性药物; 所述药物活化剂载体允许靶向递送毒性药物。

公开(公告)号：WO2007023398A3

公开(公告)日：2008-02-21

申请号：PCT/IB2006003547

申请日：2006-05-15

Applicant: UNIV GENEVE ,  LANGE NORBERT ,  CAMPO MARINO A

Inventor： LANGE NORBERT ,  CAMPO MARINO A

IPC: A61K41/00

CPC classification number: A61K41/0071 ,  A61K41/0057 ,  A61K41/0076 ,  A61K47/645 ,  A61K47/67 ,  A61N5/062 ,  B82Y5/00

Abstract: Enzyme-activatable photosensitizing polymer conjugates are disclosed for photochemotherapeutic treatment of human diseases and disorders, bacteriologic or virologic indications, cosmetic applications and other pathologic situations. These polymer conjugates may comprise a polymer carrier, a photosensitizer, a quencher, a targeting molecule and/or a biocompatibilizing unit. These macromolecular conjugates may be designed to guide to the target tissue a photosensitizing agent in an inactive, non-phototoxic form. However, upon entering the target environment, in which certain enzymes are presently active, the conjugate may release its photosensitizers in its fully active form, resulting in a highly localized activation of the photoactive agent. Also described here are methods, compositions and kits for the preparation and testing of such photochemotherapeutic conjugates.

Abstract translation: 公开了可激活光敏聚合物共轭物用于光化学治疗人类疾病和病症，细菌或病毒学适应症，美容应用和其他病理情况。 这些聚合物缀合物可以包含聚合物载体，光敏剂，猝灭剂，靶向分子和/或生物相容化单元。 这些大分子缀合物可以设计成以无活性，非光毒性形式向目标组织引导光敏剂。 然而，当进入某些酶目前活性的目标环境时，缀合物可以以其完全活性形式释放其光敏剂，导致光活性剂的高度局部化的活化。 这里还描述了用于制备和测试这种光化学治疗偶联物的方法，组合物和试剂盒。

公开(公告)号：WO2007026146A1

公开(公告)日：2007-03-08

申请号：PCT/GB2006/003215

申请日：2006-08-30

Applicant: CRUSADE LABORATORIES LIMITED ,  BROWN, Susanne Moira ,  HAMILTON, Guy Michael Gary

Inventor： BROWN, Susanne Moira ,  HAMILTON, Guy Michael Gary

IPC: A61K39/245 ,  A61K38/43 ,  A61K35/76 ,  C12N15/869 ,  C12N7/04 ,  A61P35/00

CPC classification number: A61K35/763 ,  A01K2267/0331 ,  A61K38/44 ,  A61K45/06 ,  A61K47/67 ,  B82Y5/00 ,  C12N2710/16632 ,  C12Y105/01034 ,  A61K2300/00

Abstract: The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.

Abstract translation: 使用单纯疱疹病毒（HSV）通过外源性施用所述HSV来治疗肿瘤，以及使用HSV通过与药物组合治疗来治疗肿瘤，其中HSV和/或药物在外分泌部位施用， 被披露。

公开(公告)号：WO2005084713A3

公开(公告)日：2005-10-20

申请号：PCT/GB2005000789

申请日：2005-03-04

Applicant: ML LAB PLC ,  HUIZINGA TOM J W ,  HOEBEN ROBERT C ,  NELISSEN ROB G H H ,  MOUNTAIN ANDREW

Inventor： HUIZINGA TOM J W ,  HOEBEN ROBERT C ,  NELISSEN ROB G H H ,  MOUNTAIN ANDREW

IPC: A61F2/00 ,  A61K31/00 ,  A61K47/48 ,  A61K48/00 ,  C12N5/06

CPC classification number: B82Y5/00 ,  A61F2002/30535 ,  A61F2250/0058 ,  A61K47/555 ,  A61K47/67 ,  C12N2830/008

Abstract: The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides prodrugs and adenoviral vectors comprising genes encoding prodrugs converting enzymes for simultaneous, separate or sequential use in the destruction of interface tissue allowing subsequent recementing of loose prostheses in a minimally invasive manner.

Abstract translation: 本发明涉及基因疗法在矫形矫形器无菌松动的治疗中的应用，并公开了将这种假体修复而不进行开放性修复手术的方法。 特别地，其提供前药和腺病毒载体，其包含编码前药转化酶的基因，用于同时，分别或顺序用于破坏界面组织，从而允许以微创方式接收松散假体。

公开(公告)号：WO03088913A8

公开(公告)日：2005-01-06

申请号：PCT/US0311981

申请日：2003-04-17

Applicant: CELMED ONCOLOGY USA INC ,  SERGEEVA MARIA V ,  DOPPALAPUDI VENKATA RAMANA

Inventor： SERGEEVA MARIA V ,  DOPPALAPUDI VENKATA RAMANA

IPC: A61K47/48 ,  A61K49/00 ,  C12Q1/18 ,  A61K31/4709 ,  A61K39/02 ,  C07C69/017 ,  C07D307/42 ,  C07D401/04

CPC classification number: C12Q1/18 ,  A61K47/556 ,  A61K47/65 ,  A61K47/67 ,  A61K49/0004 ,  B82Y5/00

Abstract: This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-positive and gram-negative microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, and E. cloacae. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

Abstract translation: 本发明提供了通过使微生物与有效量的本文所述的化合物接触来抑制表达肽脱甲硅烷基化酶的微生物生长的方法。 该方法抑制革兰氏阳性和革兰氏阴性微生物例如金黄色葡萄球菌，表皮葡萄球菌，肺炎克雷伯菌，产气荚膜梭菌和阴沟肠杆菌的生长。 该方法可以在体外，离体和体内实施。 还提供了一种通过向受试者施用或递送有效量的上述化合物来减轻受试者中表达肽变态酶的微生物的感染症状的方法。

公开(公告)号：WO2003106619A2

公开(公告)日：2003-12-24

申请号：PCT/US2003/014819

申请日：2003-05-12

Applicant: GENENCOR INTERNATIONAL, INC. ,  CHEN, Yiyou ,  DAY, Anthony, G. ,  EDWARDS, Cynthia ,  MURRAY, Christopher, J. ,  SCHELLENBERGER, Volker

Inventor： CHEN, Yiyou ,  DAY, Anthony, G. ,  EDWARDS, Cynthia ,  MURRAY, Christopher, J. ,  SCHELLENBERGER, Volker

IPC: C12N

CPC classification number: B82Y5/00 ,  A61K38/00 ,  A61K47/6415 ,  A61K47/67 ,  A61K47/6891 ,  A61K48/00 ,  C07K2319/00 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/70 ,  C12N9/50 ,  C12N9/86 ,  C12N15/1044 ,  C12N15/62

Abstract: The present invention provides methods and compositions relating to polypeptides engineered to bind a target and have at least two functional domains.

Abstract translation: 本发明提供了与被工程化以结合靶并具有至少两个功能结构域的多肽有关的方法和组合物。

公开(公告)号：WO03088913A2

公开(公告)日：2003-10-30

申请号：PCT/US0311981

申请日：2003-04-17

Applicant: NEWBIOTICS INC ,  SERGEEVA MARIA V ,  DOPPALAPUDI VENKATA RAMANA

Inventor： SERGEEVA MARIA V ,  DOPPALAPUDI VENKATA RAMANA

IPC: A61K47/48 ,  A61K49/00 ,  C12Q1/18 ,  A61K

CPC classification number: C12Q1/18 ,  A61K47/556 ,  A61K47/65 ,  A61K47/67 ,  A61K49/0004 ,  B82Y5/00

Abstract: This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described herein. This method inhibits the growth of gram-positive and gram-negative microorganism, e.g., S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, and E. cloacae. This method can be practiced in vitro, ex vivo and in vivo. Further provided is a method for alleviating the symptoms of an infection by a Peptide Deformylase expressing microorganism in a subject by administering or delivering to the subject an effective amount of the compound described above.

Abstract translation: 本发明提供了通过使微生物与有效量的本文所述的化合物接触来抑制表达肽脱甲硅烷基化酶的微生物生长的方法。 该方法抑制革兰氏阳性和革兰氏阴性微生物例如金黄色葡萄球菌，表皮葡萄球菌，肺炎克雷伯菌，产气荚膜梭菌和阴沟肠杆菌的生长。 该方法可以在体外，离体和体内实施。 还提供了一种通过向受试者施用或递送有效量的上述化合物来减轻受试者中表达肽变态酶的微生物的感染症状的方法。

公开(公告)号：WO2003082323A1

公开(公告)日：2003-10-09

申请号：PCT/AU2003/000381

申请日：2003-03-28

Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION ,  BOTH, Gerald, Wayne ,  LOCKETT, Trevor, John ,  MOLLOY, Peter, Laurence ,  CAMERON, Fiona, Helen ,  RUSSELL, Pamela, Joan ,  MARTINIELLO-WILKS, Rosetta ,  MOGHADDAM, Minoo, Jalali ,  SMITH, Ian, Keith

Inventor： BOTH, Gerald, Wayne ,  LOCKETT, Trevor, John ,  MOLLOY, Peter, Laurence ,  CAMERON, Fiona, Helen ,  RUSSELL, Pamela, Joan ,  MARTINIELLO-WILKS, Rosetta ,  MOGHADDAM, Minoo, Jalali ,  SMITH, Ian, Keith

IPC: A61K38/45

CPC classification number: A61K35/761 ,  A61K38/45 ,  A61K45/06 ,  A61K47/67 ,  A61K47/6901 ,  A61K48/00 ,  A61K48/0041 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10132 ,  C12N2710/10143 ,  C12N2830/008 ,  C12N2830/15 ,  A61K2300/00

Abstract: The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps(i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and(ii) administering a prodrug to the subject,wherein the engineered ovine atadenovirus comprises a promoter and a gene encoding an enzyme which converts the prodrug to a cytotoxic metabolite, the gene being under the control of the promoter.

Abstract translation: 本发明提供一种治疗受试者的实体肿瘤的方法，所述方法包括以下步骤：（i）向实体瘤递送包含工程改造的腺癌腺病毒的组合物; 并且（ii）向所述受试者施用前药，其中所述工程改造的腺癌腺病毒包含启动子和编码将所述前药转化为细胞毒性代谢物的酶的基因，所述基因处于所述启动子的控制之下。

公开(公告)号：WO2003070173A2

公开(公告)日：2003-08-28

申请号：PCT/US2003/004596

申请日：2003-02-14

Applicant: SYMPORE GMBH ,  BURNET, Michael ,  GUSE, Jan-Hinrich ,  KIM, Gene ,  BECK, Albert ,  TSOTSOU, Georgia ,  DROSTE-BOREL, Irina ,  BARKER, Laurence ,  WOLFF, Michael ,  GUTKE, Hans-Jurgen

Inventor： BURNET, Michael ,  GUSE, Jan-Hinrich ,  KIM, Gene ,  BECK, Albert ,  TSOTSOU, Georgia ,  DROSTE-BOREL, Irina ,  BARKER, Laurence ,  WOLFF, Michael ,  GUTKE, Hans-Jurgen

IPC: A61K

CPC classification number: B82Y5/00 ,  A61K47/552 ,  A61K47/556 ,  A61K47/67 ,  A61K49/0004 ,  G01N33/5047 ,  G01N33/5094

Abstract: This invention features a method of identifying a compound useful for enhancing efficacy of a therapeutic agent. The method includes incubating a compound in blood cells; separating immune cells from erythrocytic cells; and determining the ratio of the concentration of the compound in the immune cells to the concentration of the compound in the erythrocytic cells; wherein the compound comprises a transportophore and a therapeutic agent, in which the transportophore is covalently bonded to the therapeutic agent via a bond or a linker.

Abstract translation: 本发明的特征在于鉴定可用于增强治疗剂功效的化合物的方法。 该方法包括在血细胞中孵育化合物; 从红细胞中分离免疫细胞; 并确定免疫细胞中化合物浓度与红细胞中化合物浓度的比率; 其中所述化合物包含转运载体和治疗剂，其中所述转运载体通过键或接头共价键合至治疗剂。